All News
Filter News
Found 46 articles
-
ArsenalBio to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
9/8/2021
ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 12:30 p.m. ET.
-
BioSpace Movers & Shakers, July 23
7/23/2021
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer
7/19/2021
ArsenalBio, a privately held programmable cell therapy company, announced that W. Nicholas Haining, BM, BCh, is to be appointed as Chief Scientific Officer, where he will lead the company’s multi-disciplinary research and early product development efforts, leveraging more than 20 years of leadership and experience in academic medicine and biopharma.
-
Adicet Bio Announces Formation of Scientific Advisory Board
7/15/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the formation of a Scientific Advisory Board.
-
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
5/19/2021
Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, announced today the publication of its bispecific human heavy chain only antibody (TNB-409) with selective IL-2βγ receptor heterodimeric agonist activity in Scientific Reports ( www.nature.com/articles/s41598-021-90096-8 ).
-
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
5/17/2021
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the first quarter 2021.
-
IMV Appoints Dr. Michael Kalos to Board of Directors
5/11/2021
IMV continues to add industry expertise with appointment of Dr. Michael Kalos, an internationally recognized expert in T cell therapy and immunotherapy James Hall to retire at the AGM after 11 years as a board member
-
Graphite Bio Appoints Jane Grogan, Ph.D., as Chief Scientific Officer
4/27/2021
Dr. Grogan Brings More Than 20 Years of Industry Experience Building Research Teams and Executing Drug Development Strategies Across Therapeutic Areas and Modalities
-
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
4/5/2021
Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase I study (https://clinicaltrials.gov/ct2/show/NCT04540796), which is sponsored by Janssen Research & Development, LLC (Janssen)
-
ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer
3/8/2021
-- Follows recent appointments of Barbara Kosacz and Matthew Fust to ArsenalBio’s Board of Directors and Ken Drazan as Chairman of the Board -- -- Expansion of leadership will support programmable cell therapy pioneer’s continued pipeline, business and operations scale-up --
-
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
2/25/2021
Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today the appointments of renowned experts Abul K. Abbas, M.D., distinguished professor in pathology and former chair of the department of pathology at the University of California, San Francisco (UCSF)
-
Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer
1/26/2021
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021. Therapeutic options for mCRPC are limited, and those that are available imp
-
Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible.
-
ArsenalBio has entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.
-
ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
1/7/2021
-- Partnership combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development -- -- ArsenalBio employs a suite of proprietary technologies to encode synthetic biological instructions to overcome solid tumors’ complex defense systems --
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
BioSpace Announces Top New Life Sciences Companies to Watch in 2021
1/6/2021
BioSpace, Inc., the leading life sciences news and careers site, has announced their 25 selections for biopharma's most promising up-and-coming companies in 2021.
-
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
12/7/2020
Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported initial results of a Phase I trial (https://clinicaltrials.gov/ct2/show/NCT03933735) evaluating TNB-383B in Relapsed Refractory Multiple Myeloma (R/R MM) on December 5 at the 62nd American Society of Hematology Annual Conference
-
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
11/23/2020
Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies.
-
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
11/19/2020
Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecifi